Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory

Epidemiological studies have suggested that cumulative diabetic exposure, namely prolonged exposure to chronic hyperglycemia, contributes to the increased risk of cardiovascular disease (CVD) in diabetes. The formation and accumulation of advanced glycation end‐products (AGEs) have been known to progress under hyperglycemic conditions. Because AGEs‐modified collagens are hardly degraded and remain in diabetic vessels, kidneys and the heart for a long time, even after glycemic control has been achieved, AGEs could become a marker reflecting cumulative diabetic exposure. Furthermore, there is a growing body of evidence that an interaction between AGEs and the receptor for AGEs (RAGE) plays a role in the pathogenesis of CVD. In addition, AGEs induce the expression of RAGE, thus leading to sustained activation of the AGEs–RAGE axis in diabetes. Herein we review the pathological role of the AGEs–RAGE axis in CVD, focusing particularly on the phenomenon of metabolic memory, and discuss the potential clinical usefulness of measuring circulating and tissue levels of AGEs accumulation to evaluate diabetic macrovascular complications.

[1]  A. Berezin Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives. , 2016, Diabetes & metabolic syndrome.

[2]  S. Genuth,et al.  Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes , 2016, Cardiovascular Diabetology.

[3]  J. Lachin,et al.  Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up , 2016, Diabetes Care.

[4]  S. Yamagishi,et al.  Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention. , 2016, Nutrition.

[5]  S. Genuth,et al.  Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes , 2015, Cardiovascular Diabetology.

[6]  K. Jandeleit-Dahm,et al.  Linking RAGE and Nox in diabetic micro- and macrovascular complications. , 2015, Diabetes & metabolism.

[7]  R. Friedman,et al.  RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes , 2015, Diabetes.

[8]  D. Reda,et al.  Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. , 2015, The New England journal of medicine.

[9]  S. Yamagishi,et al.  Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. , 2015, International journal of cardiology.

[10]  R. Natarajan,et al.  Epigenetic mechanisms in diabetic complications and metabolic memory , 2015, Diabetologia.

[11]  S. Yamagishi,et al.  Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. , 2015, Rejuvenation research.

[12]  S. Yamagishi,et al.  Role of receptor for advanced glycation end products (RAGE) in liver disease , 2015, European Journal of Medical Research.

[13]  Hyoil Han,et al.  Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. , 2015, Diabetes research and clinical practice.

[14]  S. Yamagishi,et al.  Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications , 2015, Cardiovascular Diabetology.

[15]  B. Zinman,et al.  Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.

[16]  S. Yamagishi,et al.  Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine‐injected diabetic patients , 2014, Diabetes/metabolism research and reviews.

[17]  A. Nakashima,et al.  Ratio of Serum Levels of Ages to Soluble Form of Rage Is a Predictor of Endothelial Function Diabetes Care 1 , 2022 .

[18]  S. Yamagishi,et al.  Irbesartan inhibits advanced glycation end product-induced increase in asymmetric dimethylarginine level in mesangial cells through its anti-oxidative properties. , 2014, International journal of cardiology.

[19]  R. Simó,et al.  Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. , 2014, The Journal of endocrinology.

[20]  M. Yokoro,et al.  Role of asymmetric dimethylarginine in cardiorenal syndrome. , 2014, Current pharmaceutical design.

[21]  T. Imaizumi,et al.  Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF. , 2013, International journal of cardiology.

[22]  C. Cowie,et al.  The Association of Skin Intrinsic Fluorescence With Type 1 Diabetes Complications in the DCCT/EDIC Study , 2013, Diabetes Care.

[23]  M. Yokoro,et al.  Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction , 2013, Diabetes & vascular disease research.

[24]  I. Shimomura,et al.  Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. , 2013, Atherosclerosis.

[25]  M. Matsuzaki,et al.  Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study , 2013, Cardiovascular Diabetology.

[26]  T. Imaizumi,et al.  Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomography , 2012, Diabetes Care.

[27]  S. Yamagishi Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders. , 2012, Rejuvenation research.

[28]  K. Sasaki,et al.  Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. , 2012, Cardiovascular therapeutics.

[29]  S. Yamagishi,et al.  Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. , 2012, Metabolism: clinical and experimental.

[30]  T. Imaizumi,et al.  Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation. , 2012, International journal of cardiology.

[31]  M. Sarras,et al.  Metabolic Memory and Chronic Diabetes Complications: Potential Role for Epigenetic Mechanisms , 2012, Current Diabetes Reports.

[32]  A. Jenkins,et al.  Non‐invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non‐invasive measure of vascular dysfunction , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[33]  S. Yamagishi Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. , 2011, Current drug targets.

[34]  A. Smit,et al.  Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. , 2011, Atherosclerosis.

[35]  G. Hitman,et al.  Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes , 2011, Diabetes.

[36]  S. Yamagishi,et al.  Rosuvastatin Blocks Advanced Glycation End Products-elicited Reduction of Macrophage Cholesterol Efflux by Suppressing NADPH Oxidase Activity via Inhibition of Geranylgeranylation of Rac-1 , 2011, Hormone and Metabolic Research.

[37]  Sho-ichi Yamagishi,et al.  Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes , 2011, Experimental Gerontology.

[38]  S. Fukumoto,et al.  Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. , 2011, Metabolism: clinical and experimental.

[39]  Peter H Whincup,et al.  Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. , 2011, Archives of internal medicine.

[40]  H. Parving,et al.  Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes , 2011, Diabetes Care.

[41]  S. Yamagishi,et al.  Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). , 2010, Current drug targets.

[42]  S. Yamagishi,et al.  Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. , 2010, Frontiers in bioscience.

[43]  H. Parving,et al.  Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes , 2010, Diabetes.

[44]  Tsukasa Suzuki,et al.  Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. , 2009, Metabolism: clinical and experimental.

[45]  S. Bandinelli,et al.  Plasma Carboxymethyl‐Lysine, an Advanced Glycation End Product, and All‐Cause and Cardiovascular Disease Mortality in Older Community‐Dwelling Adults , 2009, Journal of the American Geriatrics Society.

[46]  Robert J. Anderson,et al.  Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis , 2009, Diabetes.

[47]  Biao Xu,et al.  Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. , 2009, Biochemical and biophysical research communications.

[48]  L. Ferrucci,et al.  Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women , 2009, Aging clinical and experimental research.

[49]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[50]  S. Yamagishi,et al.  Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes. , 2008, Medical hypotheses.

[51]  S. Yamagishi,et al.  Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes. , 2008, Medical hypotheses.

[52]  K. Tan,et al.  Cellular cholesterol efflux to serum is impaired in diabetic nephropathy , 2008, Diabetes/metabolism research and reviews.

[53]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[54]  K. Tan,et al.  Determinants of leukocyte adenosine triphosphate-binding cassette transporter G1 gene expression in type 2 diabetes mellitus. , 2008, Metabolism: clinical and experimental.

[55]  T. Imaizumi,et al.  Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. , 2008, Microvascular research.

[56]  S. Yamagishi,et al.  Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. , 2008, Current pharmaceutical design.

[57]  T. Imaizumi,et al.  Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects , 2007, Clinical and Experimental Medicine.

[58]  P. Libby,et al.  AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. , 2007, Atherosclerosis.

[59]  M. Laakso,et al.  Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study , 2007, Diabetologia.

[60]  S. Rahbar Novel inhibitors of glycation and AGE formation , 2007, Cell Biochemistry and Biophysics.

[61]  T. Imaizumi,et al.  Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. , 2007, Journal of the American College of Cardiology.

[62]  M. Cooper,et al.  AGE, RAGE, and ROS in diabetic nephropathy. , 2007, Seminars in nephrology.

[63]  David M Nathan,et al.  The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study , 2006, Diabetes.

[64]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[65]  T. Imaizumi,et al.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.

[66]  H. Parving,et al.  Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. , 2004, Diabetes care.

[67]  D. O'leary,et al.  Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. , 2003, The New England journal of medicine.

[68]  P. Libby Inflammation in atherosclerosis , 2002, Nature.

[69]  Jixian Wang,et al.  Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies , 2002, BMJ : British Medical Journal.

[70]  A. Schmidt,et al.  Atherosclerosis and diabetes: The rage connection , 2000, Current atherosclerosis reports.

[71]  J. Mehlsen,et al.  Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. , 1999, Diabetes care.

[72]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[73]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[74]  R. Ziegler,et al.  AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.

[75]  R. Bucala,et al.  Recent Progress in Advanced Glycation and Diabetic Vascular Disease: Role of Advanced Glycation End Product Receptors , 1996, Diabetes.

[76]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[77]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[78]  V. Monnier Nonenzymatic glycosylation, the Maillard reaction and the aging process. , 1990, Journal of gerontology.

[79]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[80]  R. LaBrie,et al.  A 12-year follow-up study of chronic schizophrenics. , 1982, Hospital & community psychiatry.

[81]  V. J. Stevens,et al.  Diabetic cataract formation: potential role of glycosylation of lens crystallins. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[82]  S. Yamagishi,et al.  Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. , 2013, The American journal of pathology.

[83]  J. Manitius,et al.  Advanced glycation end products and arterial stiffness in patients with diabetic nephropathy and patients with chronic kidney disease without diabetes. , 2013, Polskie Archiwum Medycyny Wewnetrznej.

[84]  A. Avogaro,et al.  Endothelial progenitor cells and vascular biology in diabetes mellitus: current knowledge and future perspectives. , 2005, Current diabetes reviews.

[85]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[86]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.